Vanda Pharmaceuticals Stock Discussion

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide) 
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

$Vanda Pharmaceuticals (VNDA.US)$  Tradipitant Nda Review for Gastroparesis Ongoing; Pdufa Date of September 18, 2024

$Vanda Pharmaceuticals (VNDA.US)$
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are NOT in the Best Interests of the Company and its Shareholders
On June 19, 2024, Vanda Pharmaceuticals (Nasdaq: VNDA) announced its Board of Directors REJECTED unsolicited takeover proposals from Cycle Group Holdings and Future Pak The offers were $8.00 per share in cash from Cycle Group and $8.50-$9.00 per share in cash plus Contingent Value Rights (CVRs) from F...

$Vanda Pharmaceuticals (VNDA.US)$ Easy buy and hold. lol Offer of 8.50-9.00 on the table.

$Vanda Pharmaceuticals (VNDA.US)$
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

$Vanda Pharmaceuticals (VNDA.US)$ Future Pak Increases Cash Portion Of Its Offer For Vanda Pharmaceuticals By $0.75-$1.25 To $8.50-$9.00 Per Share

$Vanda Pharmaceuticals (VNDA.US)$ Reuters· 8 mins ago
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 per Share

$Vanda Pharmaceuticals (VNDA.US)$ Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S
Benzinga· 1 min ago

$Vanda Pharmaceuticals (VNDA.US)$
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency...